NFKB1 and Miyoshi myopathy: Emerging approaches targeting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling or heparanase-mediated extracellular signal-regulated kinase activation remain experimental.[16] The complexity of MM resistance mechanisms necessitates systematic analysis of current research landscapes and predictive identification of novel therapeutic targets.